Please note that the sessions and live Q&A’s during the SIOP 2020 Virtual Congress will take place according to Eastern Daylight Time (EDT/UTC-4).
Thursday, October 15th, 2020
OPTIMISING PATIENT MANAGEMENT WITH ANTI-GD2 IMMUNOTHERAPY
SYMPOSIUM ORGANIZED AND SPONSORED BY EUSAPharma
This session is not included in main conference CME/CPD credit
07:30-08:45 EDT
Chair: Dr. Giuseppe Barone, UK
07:30 – 07:35 WELCOME AND INTRODUCTIONS
Dr. Giuseppe Barone, UK
07:35 – 07:50 Treatment outcomes with Qarziba as front-line maintenance therapy
Dr. Vassilios Papadakis, Greece
07:50 – 08:05 Enhancing the patient experience: Strategies for managing adverse events
Dr. Giuseppe Barone, UK
08:05 – 08:25 Qarziba in the clinic: Patient case studies discussion
Dr. Giuseppe Barone, UK and Dr. Vassilios Papadakis, Greece
08:25 – 08:45 LIVE Q&A SESSION AND CLOSING
All Faculty
BUILDING BRIDGES TO ENSURE BEST POSSIBLE OUTCOMES FOR ALL PEOPLE WITH ALL
SYMPOSIUM ORGANIZED AND SPONSORED BY SERVIER
This session is not included in main conference CME/CPD credit
09:40-12:00 EDT
Chairs: Dan Douer & Scott Howard, USA
09:40 – 09:45 Welcome to the Building ALL Bridges Symposium & welcome from the Satellite Hub in Italy
Carmelo Rizzari, Italy
09:45 – 09:48 Welcome from the Satellite hubs: Canada
Donna Johnston, Canada
09:48 – 09:51 Welcome from the Satellite hubs: The Netherlands
Gertjan Kaspers, The Netherlands
09:51 – 09:54 Welcome from the Satellite hubs: slovakia
Alexandra Kolenova, Slovakia
09:54 – 09:59 Introduction to the Symposium objectives
Dan Douer, USA
09:59 – 10:14 What are the biological difference between ALL in children and adults?
Stephen Hunger, USA
10:14 – 10:24 Main steps in the history of the development of ALL treatment concept (Pediatric)
Carmelo Rizzari, Italy
10:24– 10:34 Main steps in the history of the development of ALL treatment concept (ADULTS)
Dan Douer, USA
10:34 – 10:54 Differences in treatment toxicities between ALL children and adults. Is there a cutoff age?
Kjeld Schmiegelow, Sweden
10:54 – 11:09 Immunotherapy and CAR-T cells: comparing experiences in children
Andrea Biondi, Italy
11:09 – 11:24 Immunotherapy and CAR-T cells: comparing experiences in adults
Nicolas Boissel, France
11:24 – 11:44 Best available treatment for AYA ALL patients
Rob Pieters, The Netherlands
11:44 – 11:54 Questions and wrap up of the first session
Scott Howard, USA
11:54 – 12:00 Call to Action: Building ALL Bridges
Carmelo Rizzari, Italy and Dan Douer, USA
Let us be practical about collaboration. Experience shared
SYMPOSIUM ORGANIZED AND SPONSORED BY SERVIER
This session is not included in main conference CME/CPD credit
12:20-13:45 EDT
12:20 – 12:40 Age-adaption in the newly designed ALLTogether protocol: PI, Mats Heyman talks about reasons for adaptation and how these adaptations will be evaluated
Mats Heyman, Sweden
12:40 – 13:00 Practicalities of working together. Experience from Italy
Andrea Biondi & Renato Bassan, Italy
13:00 – 13:20 Practicalities of working together. Experience from the netherlands
Rob Pieters & Lotte v/d Wagen, the Netherlands
13:20 – 13:30 Practicalities of working together. Experience from france
Nicolas Boissel, France
13:30 – 13:40 Practicalities of working together. Experience from slovakia
Alexandra Kolenova, Slovakia
13:40 – 13:45 next steps
Scott Howard, USA
ON THE HORIZON: IMMUNOTHERAPY STRATEGIES FOR RELAPSED/REFRACTORY HIGH-RISK NEUROBLASTOMA
SYMPOSIUM ORGANIZED AND SPONSORED BY Ology Medical Education
* This session is not included in main conference CME/CPD credit
*Independent CME-accredited satellite symposium
*Jointly provided by Postgraduate Institute for Medicine and Ology Medical Education and supported by an independent educational grant from Y-mAbs Therapeutics, Inc.
12:00-13:30 EDT
Chair: Susan Cohn, USA
12:00 – 12:10: WELCOME AND INTRODUCTION
Susan Cohn, USA
12:10 – 12:35: Unmet needs in R/R high-risk neuroblastoma: rising to the challenge
Susan Cohn, USA
12:35 – 13:00: Targeted antibody-based immunotherapy approaches in the R/R setting: evidence and perspectives
Daniel Morgenstern, Canada
13:00 – 13:25: Optimizing clinical management and treatment outcomes: a multidisciplinary approach
Jaume Mora, Spain
13:25 – 14:00: LIVE SUMMARY SESSION
All Faculty, the discussion will continue as Meet the Experts Q&A in the chat room until 14:00
Friday, October 16th, 2020
EPIGENETIC MODIFIERS IN PEDIATRIC ONCOLOGY
SYMPOSIUM ORGANIZED AND SPONSORED BY Bristol-Myers Squibb
This session is not included in main conference CME/CPD credit
07:30-08:30 EDT
Chair: Eric Bouffet, Canada
07:30 – 07:35 OPENING REMARKS
Eric Bouffet, Canada
07:35 – 07:50 HDAC INHIBITION
Kimberly Stegmaier, USA
07:50 – 08:05 BET INHIBITION
Franck Bourdeaut, France
08:05 – 08:20 MENIN INHIBITION
Michel Zwaan, Netherlands
08:20 – 08:30 LIVE Q&A SESSION
All Faculty
IMPROVING CHILDREN CARE WITH TEMOZOLOMIDE ORAL SUSPENSION
PRODUCT THEATRE SESSION ORGANIZED AND SPONSORED BY Orphelia Pharma
This session is not included in main conference CME/CPD credit
09:15-09:35 EDT
09:15 – 09:22 Temozolomide in treatment of relapsed or refractory pediatric tumors
Lucas Moreno, Spain
09:22 – 09:29 Efficacy and safety of temozolomide-based regimen for relapsed or refractory neuroblastoma
Dominique Valteau-Couanet, France
09:29 – 09:33 Development of Kimozo: a ready-to-use and taste masked oral suspension of temozolomide
Caroline Lemarchand, France
